Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Windtree Therapeutics stock

Own Windtree Therapeutics stock in just a few minutes.

Windtree Therapeutics, Inc is a biotechnology business based in the US. Windtree Therapeutics shares (WINT) are listed on the NASDAQ and all prices are listed in US Dollars. Windtree Therapeutics employs 31 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Windtree Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – WINT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Windtree Therapeutics share price

Use our graph to track the performance of WINT stocks over time.

Windtree Therapeutics shares at a glance

Information last updated 2021-04-23.
52-week range$2.01 - $10.06
50-day moving average $2.95
200-day moving average $5.15
Wall St. target price$10.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.13

Buy Windtree Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Windtree Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Windtree Therapeutics financials

Gross profit TTM $-15,373,000
Return on assets TTM -15.86%
Return on equity TTM -45.08%
Profit margin 0%
Book value $4.11
Market capitalisation $57 million

TTM: trailing 12 months

Shorting Windtree Therapeutics shares

There are currently 129,001 Windtree Therapeutics shares held short by investors – that's known as Windtree Therapeutics's "short interest". This figure is 18.1% down from 157,546 last month.

There are a few different ways that this level of interest in shorting Windtree Therapeutics shares can be evaluated.

Windtree Therapeutics's "short interest ratio" (SIR)

Windtree Therapeutics's "short interest ratio" (SIR) is the quantity of Windtree Therapeutics shares currently shorted divided by the average quantity of Windtree Therapeutics shares traded daily (recently around 716672.22222222). Windtree Therapeutics's SIR currently stands at 0.18. In other words for every 100,000 Windtree Therapeutics shares traded daily on the market, roughly 180 shares are currently held short.

However Windtree Therapeutics's short interest can also be evaluated against the total number of Windtree Therapeutics shares, or, against the total number of tradable Windtree Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Windtree Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Windtree Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.0074% of the tradable shares (for every 100,000 tradable Windtree Therapeutics shares, roughly 7 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Windtree Therapeutics.

Find out more about how you can short Windtree Therapeutics stock.

Windtree Therapeutics share dividends

We're not expecting Windtree Therapeutics to pay a dividend over the next 12 months.

Have Windtree Therapeutics's shares ever split?

Windtree Therapeutics's shares were split on a 1:3 basis on 28 April 2020. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Windtree Therapeutics shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Windtree Therapeutics shares which in turn could have impacted Windtree Therapeutics's share price.

Windtree Therapeutics share price volatility

Over the last 12 months, Windtree Therapeutics's shares have ranged in value from as little as $2.01 up to $10.06. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Windtree Therapeutics's is -0.1511. This would suggest that Windtree Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Windtree Therapeutics has bucked the trend.

Windtree Therapeutics overview

Windtree Therapeutics, Inc. , a clinical-stage biotechnology and medical device company, focuses on the development of therapeutics for the treatment of acute pulmonary and cardiovascular diseases. Its lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company has a collaboration with University of Milan-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site